The risk of adverse cardiovascular events from varenicline balanced against the benefits in mortality from smoking cessation

Nicotine and Tobacco Research

Volumn 14, Issue 12, 2012, Pages 1391-1393

  Kistler, Christine E ^a   Goldstein, Adam O ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO; VARENICLINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; HUMAN; META ANALYSIS; MORTALITY; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMOKING CESSATION; TOBACCO DEPENDENCE;

BENZAZEPINES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; RISK ASSESSMENT; SMOKING; SMOKING CESSATION;

EID: 84868304334     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts028     Document Type: Article

References (13)

1. Brophy, J. M. (2011). ACP Journal Club. Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users. Annals of Internal Medicine, 155, JC4--JC5. doi:10.1059/0003-4819-155-8-201110180-02005
2. Cahill, K., Stead, L. F., & Lancaster, T. (2007). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (1), CD006103. doi:10.1002/14651858. CD006103.pub2
3. Garza, D., Murphy, M., Tseng, L. J., Riordan, H. J., & Chatterjee, A. (2011). A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biological Psychiatry, 69, 1075-1082. doi:10.1016/j.biopsych.2010.12.005
4. Hays, J. T. (2011). Varenicline for smoking cessation: Is it a heartbreaker? Canadian Medical Association Journal, 183, 1346-1347. doi:10.1503/cmaj.110804
5. Keating, G. M., & Lyseng-Williamson, K. A. (2010). Varenicline: A pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics, 28, 231-254. doi:10.2165/11204380-000000000-00000
6. Kenfield, S. A., Stampfer, M. J., Rosner, B. A., & Colditz, G. A. (2008). Smoking and smoking cessation in relation to mortality in women. Journal of the American Medical Association, 299, 2037-2047. doi:10.1001/jama.299.17.2037
7. Mann, D. (2011). Stop smoking drug chantix ups risk of heart problems. Retrieved from http://www.abc12.com/story/15022786/stop-smoking-drug-chantix-ups-risk-of-heart-problems-study?clienttype=printable
8. Moore, T. J., Cohen, M. R., & Furberg, C. D. (2008). Strong safety signal seen for new varenicline risks. Institute for safe medication practices. Retrieved from http://www.ismp.org/docs/vareniclinestudy.asp
9. Politi, M. C., Han, P. K., & Col, N. F. (2007). Communicating the uncertainty of harms and benefits of medical interventions. Medical Decision Making, 27, 681-695. doi:10.1177/027298 9X07307270
10. Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011). Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. Canadian Medical Association Journal, 12, 1359-1366. doi:10.1503/cmaj.110218
11. Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010). Psychiatric adverse events in randomized, double-blind, placebocontrolled clinical trials of varenicline: A pooled analysis. Drug Safety, 33, 289-301. doi:10.2165/11319180-000000000-000003
12. Tobacco Use and Dependence Guideline Panel. (2008). Treating tobacco use and dependence: 2008 Update. Retrieved from http://www.ahrq.gov/path/tobacco.htm
13. Wilson, P. W., D ' Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837-1847. doi:10.1161/01.CIR.97.18.1837